From antiangiogenesis to hypoxia: current research and future directions

References

• IdeAGBakerNHWarrenSLVascularization of the Brown–Pearce rabbit epithelioma transplant as seen in the transparent ear chamberAJR Am J Roentgenol193942891899
   Google Scholar
• AlgireGHChalkleyHWVascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplantsJ Natl Cancer Inst194567385
   Web of Science ®Google Scholar
• GreeneHSHeterologous transplantation of mammalian tumors: I. The transfer of rabbit tumors to alien speciesJ Exp Med194173446147419871090
   PubMedGoogle Scholar
• FolkmanJColePZimmermanSTumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segmentAnn Surg196616434915025951515
   PubMed Web of Science ®Google Scholar
• GimbroneMAAsterRHCotranRSCorkeryJJandlJHFolkmanJPreservation of vascular integrity in organs perfused in vitro with a platelet-rich mediumNature1969222518833365775827
   PubMed Web of Science ®Google Scholar
• FolkmanJTumor angiogenesis: therapeutic implicationsN Engl J Med197128521118211864938153
   PubMed Web of Science ®Google Scholar
• BoehmTFolkmanJBrowderTO’ReillyMSAntiangiogenic therapy of experimental cancer does not induce acquired drug resistanceNature199739066584044079389480
   PubMed Web of Science ®Google Scholar
• FolkmanJSeminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesisN Engl J Med199533326175717637491141
   PubMed Web of Science ®Google Scholar
• ShingYFolkmanJSullivanRButterfieldCMurrayJKlagsbrunMHeparin affinity: purification of a tumor-derived capillary endothelial cell growth factorScience19842234642129612996199844
   PubMed Web of Science ®Google Scholar
• FolkmanJKlagsbrunMAngiogenic factorsScience198723547874424472432664
   PubMed Web of Science ®Google Scholar
• KeckPJHauserSDKriviGVascular permeability factor, an endothelial cell mitogen related to PDGFScience19892464935130913122479987
   PubMed Web of Science ®Google Scholar
• LeungDWCachianesGKuangWJGoeddelDVFerraraNVascular endothelial growth factor is a secreted angiogenic mitogenScience19892464935130613092479986
   PubMed Web of Science ®Google Scholar
• AlonTHemoIItinAPe’erJStoneJKeshetEVascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurityNat Med1995110102410287489357
   PubMed Web of Science ®Google Scholar
• FerraraNDavis-SmythTThe biology of vascular endothelial growth factorEndocr Rev19971814259034784
   PubMed Web of Science ®Google Scholar
• DavisSAldrichTHJonesPFIsolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloningCell1996877116111698980223
   PubMed Web of Science ®Google Scholar
• HolashJMaisonpierrePCComptonDVessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGFScience199928454221994199810373119
   PubMed Web of Science ®Google Scholar
• KochAEPolveriniPJKunkelSLInterleukin-8 as a macro-phage- derived mediator of angiogenesisScience19922585089179818011281554
   PubMed Web of Science ®Google Scholar
• StrieterRMKunkelSLElnerVMInterleukin-8. A corneal factor that induces neovascularizationAm J Pathol19921416127912841281615
   PubMed Web of Science ®Google Scholar
• KandelJBossy-WetzelERadvanyiFKlagsbrunMFolkmanJHanahanDNeovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcomaCell1991666109511041717155
   PubMed Web of Science ®Google Scholar
• HanahanDFolkmanJPatterns and emerging mechanisms of the angiogenic switch during tumorigenesisCell19968633533648756718
   PubMed Web of Science ®Google Scholar
• D’AmatoRJLoughnanMSFlynnEFolkmanJThalidomide is an inhibitor of angiogenesisProc Natl Acad Sci U S A1994919408240857513432
   PubMed Web of Science ®Google Scholar
• TsengJEGlissonBSKhuriFRPhase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neckCancer20019292364237311745292
   PubMed Web of Science ®Google Scholar
• FiggWDDahutWDurayPA randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgenin-dependent prostate cancerClin Cancer Res2001771888189311448901
   PubMed Web of Science ®Google Scholar
• StadlerWMKuzelTShapiroCSosmanJClarkJVogelzangNJMulti-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinomaJ Clin Oncol19991782541254510561320
   PubMed Web of Science ®Google Scholar
• LogothetisCJWuKKFinnLDPhase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancerClin Cancer Res2001751198120311350884
   PubMed Web of Science ®Google Scholar
• O’ReillyMSHolmgrenLShingYAngiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinomaCell19947923153287525077
   PubMed Web of Science ®Google Scholar
• BeerepootLVWitteveenEOGroenewegenGRecombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety studyClin Cancer Res20039114025403314519623
   PubMed Web of Science ®Google Scholar
• SoffGAWangHCundiffDLIn vivo generation of angiostatin isoforms by administration of a plasminogen activator and a free sulfhydryl donor: a phase I study of an angiostatic cocktail of tissue plasminogen activator and mesnaClin Cancer Res200511176218622516144924
   PubMed Web of Science ®Google Scholar
• O’ReillyMSBoehmTShingYEndostatin: an endogenous inhibitor of angiogenesis and tumor growthCell19978822772859008168
   PubMed Web of Science ®Google Scholar
• HerbstRSHessKRTranHTPhase I study of recombinant human endostatin in patients with advanced solid tumorsJ Clin Oncol200220183792380312228199
   PubMed Web of Science ®Google Scholar
• KulkeMHBergslandEKRyanDPPhase II study of recombinant human endostatin in patients with advanced neuroendocrine tumorsJ Clin Oncol200624223555356116877721
   PubMed Web of Science ®Google Scholar
• MarkovicSNSumanVJRaoRAA phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanomaAm J Clin Oncol200730330330917551310
   PubMed Web of Science ®Google Scholar
• BakerLHRowinskyEKMendelsonDRandomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcomaJ Clin Oncol200826345583558818981463
   PubMed Web of Science ®Google Scholar
• FuryMGZahalskyAWongRA phase II study of SU5416 in patients with advanced or recurrent head and neck cancersInvest New Drugs200725216517216983506
   PubMed Web of Science ®Google Scholar
• RobozGJGilesFJListAFPhase 1study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndromeLeukemia200620695295716617323
   PubMed Web of Science ®Google Scholar
• YangJCHaworthLSherryRMA randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancerN Engl J Med2003349542743412890841
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
   PubMed Web of Science ®Google Scholar
• van CutsemEVervenneWLBennounaJPhase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancerJ Clin Oncol200927132231223719307500
   PubMed Web of Science ®Google Scholar
• SaltzLBClarkeSDiaz-RubioEBevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III studyJ Clin Oncol200826122013201918421054
   PubMed Web of Science ®Google Scholar
• MillerKWangMGralowJPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerN Engl J Med2007357262666267618160686
   PubMed Web of Science ®Google Scholar
• EscudierBBellmuntJNegrierSPhase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survivalJ Clin Oncol201028132144215020368553
   PubMed Web of Science ®Google Scholar
• GiantonioBJCatalanoPJMeropolNJBevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200J Clin Oncol200725121539154417442997
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
   PubMed Web of Science ®Google Scholar
• KabbinavarFFHambletonJMassRDHurwitzHIBergslandESarkarSCombined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancerJ Clin Oncol200523163706371215867200
   PubMed Web of Science ®Google Scholar
• FaconTMaryJYHulinCMelphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trialLancet200737095941209121817920916
   PubMed Web of Science ®Google Scholar
• SinghalSMehtaJDesikanRAntitumor activity of thalidomide in refractory multiple myelomaN Engl J Med1999341211565157110564685
   PubMed Web of Science ®Google Scholar
• LeeCGHeijnMdi TomasoEAnti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditionsCancer Res200060195565557011034104
   PubMed Web of Science ®Google Scholar
• JainRKNormalization of tumor vasculature: an emerging concept in antiangiogenic therapyScience20053075706586215637262
   PubMed Web of Science ®Google Scholar
• FukumuraDDudaDGMunnLLJainRKTumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical modelsMicrocirculation201017320622520374484
   PubMed Web of Science ®Google Scholar
• CasanovasOHicklinDJBergersGHanahanDDrug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumorsCancer Cell20058429930916226705
   PubMed Web of Science ®Google Scholar
• EllisLMHicklinDJVEGF-targeted therapy: mechanisms of anti-tumour activityNat Rev Cancer20088857959118596824
   PubMed Web of Science ®Google Scholar
• SemenzaGLTargeting HIF-1 for cancer therapyNat Rev Cancer200331072173213130303
   PubMed Web of Science ®Google Scholar
• ElsonDAThurstonGHuangLEInduction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alphaGenes Dev200115192520253211581158
   PubMed Web of Science ®Google Scholar
• MazzoneMDettoriDLeite de OliveiraRHeterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalizationCell2009136583985119217150
   PubMed Web of Science ®Google Scholar
• LamszusKKunkelPWestphalMInvasion as limitation to antiangiogenic glioma therapyActa Neurochir Suppl20038816917714531575
   PubMedGoogle Scholar
• BergersGHanahanDModes of resistance to anti-angiogenic therapyNat Rev Cancer20088859260318650835
   PubMed Web of Science ®Google Scholar
• Lucio-EterovicAKPiaoYde GrootJFMediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapyClin Cancer Res200915144589459919567589
   PubMed Web of Science ®Google Scholar
• Paez-RibesMAllenEHudockJAntiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasisCancer Cell200915322023119249680
   PubMed Web of Science ®Google Scholar
• EbosJMLeeCRCruz-MunozWBjarnasonGAChristensenJGKerbelRSAccelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesisCancer Cell200915323223919249681
   PubMed Web of Science ®Google Scholar
• NordenADYoungGSSetayeshKBevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrenceNeurology2008701077978718316689
   PubMed Web of Science ®Google Scholar
• VerhoeffJJvan TellingenOClaesAConcerns about antiangiogenic treatment in patients with glioblastoma multiformeBMC Cancer2009944420015387
   PubMed Web of Science ®Google Scholar
• BertoutJAPatelSASimonMCThe impact of O2 availability on human cancerNat Rev Cancer200881296797518987634
   PubMed Web of Science ®Google Scholar
• HuangLEBunnHFHypoxia-inducible factor and its biomedical relevanceJ Biol Chem200327822195751957812639949
   PubMed Web of Science ®Google Scholar
• KaelinWGJrRatcliffePJOxygen sensing by metazoans: the central role of the HIF hydroxylase pathwayMol Cell200830439340218498744
   PubMed Web of Science ®Google Scholar
• HarrisALHypoxia – a key regulatory factor in tumour growthNat Rev Cancer200221384711902584
   PubMed Web of Science ®Google Scholar
• HuangLEBindraRSGlazerPMHarrisALHypoxia-induced genetic instability – a calculated mechanism underlying tumor progressionJ Mol Med200785213914817180667
   PubMed Web of Science ®Google Scholar
• BristowRGHillRPHypoxia and metabolism. Hypoxia, DNA repair and genetic instabilityNat Rev Cancer20088318019218273037
   PubMed Web of Science ®Google Scholar
• HuangLECarrot and stick: HIF-alpha engages c-Myc in hypoxic adaptationCell Death Differ200841567267718188166
   PubMed Web of Science ®Google Scholar
• GordanJDLalPDondetiVRHIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinomaCancer Cell200814643544619061835
   PubMed Web of Science ®Google Scholar
• KoshijiMToKKHammerSHIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expressionMol Cell200517679380315780936
   PubMed Web of Science ®Google Scholar
• ToKKSedelnikovaOASamonsMBonnerWMHuangLEThe phosphorylation status of PAS-B distinguishes HIF-1alpha from HIF-2alpha in NBS1 repressionEMBO J200625204784479417024177
   PubMed Web of Science ®Google Scholar
• KoshijiMKageyamaYPeteEAHorikawaIBarrettJCHuangLEHIF-1alpha induces cell cycle arrest by functionally counteracting MycEMBO J20042391949195615071503
   PubMed Web of Science ®Google Scholar
• YooYGChristensenJHuangLEHIF-1α confers aggressive malignant traits on human tumor cells independent of its canonical transcriptional functionCancer Res
   Web of Science ®Google Scholar
• ToKKKoshijiMHammerSHuangLEGenetic instability: the dark side of the hypoxic responseCell Cycle20054788188215970707
   PubMed Web of Science ®Google Scholar
• PietrasKHanahanDA multitargeted, metronomic, and maximum-tolerated dose ‘chemo-switch’ regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancerJ Clin Oncol200523593995215557593
   PubMed Web of Science ®Google Scholar
• MelilloGInhibiting hypoxia-inducible factor 1 for cancer therapyMol Cancer Res20064960160516940159
   PubMed Web of Science ®Google Scholar
• RapisardaAUranchimegBSordetOPommierYShoemakerRHMelilloGTopoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implicationsCancer Res20046441475148214983893
   PubMed Web of Science ®Google Scholar
• RapisardaAHollingsheadMUranchimegBIncreased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibitionMol Cancer Ther2009871867187719584228
   PubMed Web of Science ®Google Scholar